This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders  • Neoplasms  • Drug Therapy  • Drug Therapy, Other  • Hematology/ Hematologic Malignancies  • Leukemias/ Lymphomas  • Alert me on articles by topic  Social Bookmarking   What's this?

Wolfram Sterry, MD; Lucie Heinzerling, MD

Arch Dermatol. 2008;144(6):786-787.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The 2 articles in this issue of the Archives on cutaneous T-cell lymphoma (CTCL)^1-2 highlight several developments related to clinical research in this field. By introducing the term cutaneous T-cell lymphoma in 1980, Edelson³ helped to bridge the gap in communication between dermatologists, talking of reticulohistiocytoma and mycosis fungoides (MF), and hematooncologists, dealing with non-Hodgkin lymphoma and Hodgkin disease. The initial advantage of this unifying concept later became an obstacle for further progress, since some researchers and clinicians lumped together all CTCLs of the skin into 1 disease entity, missing differences in clinical course and therapeutic responses between, for example, MF and Sézary syndrome. It was with the publication of the European Organization for Research and Treatment of Cancer (EORTC)⁴ classification of cutaneous lymphomas in 1997 that these differences were broadly acknowledged, finally also by the World Health Organization (WHO) pathology group together with . . . [Full Text of this Article]

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Alibert Lymphoma: Renaming Mycosis Fungoides
Lessin
Arch Dermatol 2009;145:209-210.
FULL TEXT